Microbiology testing market seen reaching $16.41 billion by 2035

Market Research Future forecasts the global microbiology testing market will grow from $7.18 billion in 2026 to $16.41 billion by 2035, driven by antimicrobial-resistance surveillance mandates, laboratory automation and faster molecular diagnostics. The outlook points to stronger demand across hospitals, pharma quality control and point-of-care testing as labs shift away from slower culture-based workflows.

Why it matters: - Microbiology testing is moving from a back-office lab function to a core public-health and clinical decision tool. - Growth is being fueled by antimicrobial resistance surveillance, faster pathogen identification and automation that helps labs do more with fewer staff. - The shift matters for hospitals, pharmaceutical quality control, governments and diagnostics vendors because it raises testing volume and expands the addressable market.

What happened: - Market Research Future projected the global microbiology testing market will reach $16.41 billion by 2035, up from $7.18 billion in 2026. - The forecast implies a 9.6% compound annual growth rate for 2026 through 2035. - The market was estimated at $6.55 billion in 2025. - The report was published June 23, 2026. - The company made sample and customization requests available through the sample request page and customization page.

The details: - Antimicrobial resistance surveillance mandates are widening demand for microbiology testing across clinical labs. - The World Health Organization reported that drug-resistant illnesses killed 1.27 million people in 2019 and could cause 10 million deaths a year by 2050 if unchecked. - Governments across G7 and G20 nations have committed about $4.8 billion in AMR surveillance and stewardship financing between 2023 and 2025. - Total laboratory automation platforms can cut manual handling by up to 70% and allow one technologist to manage workloads that previously required three. - Capital spending on laboratory automation platforms reached $1.2 billion in 2024 and is projected to double by 2030. - Multiplex PCR panels that detect 20 or more pathogens in one to two hours are becoming routine in many settings. - Hospitals using syndromic molecular panels report a 35% reduction in time to targeted therapy and a 22% decrease in unnecessary broad-spectrum antibiotic use. - In September 2024, bioMérieux launched the BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini, a CLIA-waived point-of-care multiplex PCR test that identifies five common viral and bacterial causes of respiratory tract infections in about 15 minutes.

Between the lines: - The market is being pulled by regulation and workforce pressure, not optional spending. - Culture-based testing remains the dominant technology because it is still the regulatory standard for confirmatory testing. - Molecular diagnostics is the fastest-growing technology segment because it shortens time to treatment and supports higher-complexity care. - Reagents and consumables remain the biggest product category because they sit inside recurring procurement cycles. - Hospitals and diagnostic laboratories remain the largest end-user segment because national procurement and reference lab workflows concentrate volume. - The market is moderately concentrated, with the top five companies controlling an estimated 48% to 55% of global revenue. - Competition splits between broad diagnostics leaders, molecular specialists and niche food-safety or environmental monitoring players.

What's next: - By 2030, AI-augmented diagnostic decision support is expected to become central to microbiology lab operations. - An estimated 40% of high-complexity microbiology labs in OECD countries are expected to deploy AI-augmented colony readers and susceptibility prediction tools. - Cloud platforms that aggregate anonymized susceptibility data could create a new subscription revenue layer for pharma, public health agencies and insurers. - Decentralized and near-patient testing is expected to expand in the early 2030s as microfluidic cartridges and isothermal amplification improve. - Investment in CLIA-waived and CE-marked point-of-care microbiology platforms exceeded $700 million in 2024, signaling a broader move beyond centralized reference labs.

The bottom line: - Microbiology testing is set for sustained double-digit-style expansion as AMR surveillance, automation and rapid molecular diagnostics reshape how infections are detected and managed.